spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  nocturia 

 HSMN NewsFeed - 7 Mar 2017
U.S. FDA Approves Serenity Pharmaceutical’s Noctiva(TM) (desmopressin acetate) – the First Drug Approved for the Treatment of Nocturia
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 May 2013
Astellas Receives Marketing Authorization for VESOMNI(TM) from the Netherlands Medicines Evaluation Board
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 30 Oct 2012
European Commission approves Cialis(R) (tadalafil) tablets for the treatment of the signs and symptoms of benign prostatic hyperplasia
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 29 Aug 2012
U.S. FDA Grants Priority Review of ZYTIGA(R) (abiraterone acetate) sNDA for Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2011
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 8 Apr 2011
Antares Pharma Announces FDA Acceptance of Anturol(R) NDA for Filing
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 May 2010
Recordati Signs an Agreement With Zambon for the Co-Marketing of Silodosin in France
Biopharmaceuticals Urology Licensing
 HSMN NewsFeed - 1 Apr 2010
Allergan and Serenity Pharmaceuticals Enter into Global Agreement for the Treatment of Nocturia
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Feb 2010
Silodosin (Urorec(R)/Silodyx) Approved by the European Commission for the Treatment of the Signs and Symptoms of BPH (Benign Prostatic Hyperplasia)
Biopharmaceuticals Urology Regulatory
 HSMN NewsFeed - 9 Dec 2009
New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
Biopharmaceuticals Urology
 HSMN NewsFeed - 26 Oct 2009
ProtekMed Introduces the Tru-flo(TM) Urinary Catheter Valve
Devices Urology
 HSMN NewsFeed - 17 Aug 2009
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 2 Jun 2009
Pfizer Introduces New Treatment And Support Plan For Patients With Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 May 2009
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Biopharmaceuticals Urology
 HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 8 May 2009
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 Apr 2009
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2009
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals Urology
 HSMN NewsFeed - 6 Mar 2009
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 27 Jan 2009
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 31 Oct 2008
Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 8 Oct 2008
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals FDA Urology
 HSMN NewsFeed - 19 Jun 2008
FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 26 Mar 2008
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 18 Jan 2008
Enlarged Prostate Treatment Study Shows Combination of AVODART(R) and Tamsulosin Provides Greater Benefit Than Either Medication Alone
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Jan 2008
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 Oct 2007
Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
Biopharmaceuticals Neurology Drug Delivery
 HSMN NewsFeed - 4 Sep 2007
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 May 2007
Nymox Announces New Positive Results from 3 1/2 Year Study of NX-1207 for Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 19 Apr 2007
Antares Pharma Announces Positive Results from Application Site Study for ANTUROL(R)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 19 Mar 2007
Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 14 Nov 2006
New Data on Otsuka's Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
Sosei Business Strategy Update and Portfolio Review
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Nymox Reports Positive New Efficacy Data for Benign Prostatic Hyperplasia Drug
Biopharmaceuticals Urology FDA
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
nocturia
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!